The global glioma market was valued at USD 1.03 Billion in 2025, with North America holding a significant market share. The market is driven by the rising innovation in glioma therapies and increased regulatory approvals of advanced medications. It is expected to grow at a CAGR of 3.22% during the forecast period of 2026-2035, with the values likely to attain USD 1.41 Billion by 2035.
Base Year
Historical Period
Forecast Period
The rising burden of glioma along with the growing aging population more susceptible to developing this brain tumor is expected to augment the market demand.
One of the major North America glioma market trends is the surge in approvals of advanced glioma therapies and diagnostic methods by the health regulatory bodies.
Increased innovation in treatment modalities and the growing emphasis on personalized therapeutic approaches are projected to elevate the market value.
Compound Annual Growth Rate
3.22%
Value in USD Billion
2026-2035
*this image is indicative*
Glioma is a tumor occurring in the brain or other locations in the nervous system such as the spinal cord and brain stem. Advancements in diagnostic technologies, including magnetic resonance imaging (MRI), positron emission tomography (PET), and molecular diagnostics, are contributing to the market expansion by increasing the detection rate, thus, driving the demand for glioma therapies. Further, the rising innovation in treatment modalities and the emphasis on personalized therapeutic approaches are expected to support the North America glioma market growth.
Glioma is considered one of the most common forms of neoplasm in the central nervous system (CNS) originating from glial cells. It is estimated that 6 cases of gliomas are diagnosed per 100,000 individuals annually in the United States, accounting for 20,000 newly diagnosed patients with this primary brain tumor. In addition, gliomas occur most commonly in adults aged between 45 and 65 years. Recent data reveals that around 81.7% of all primary brain tumors are diagnosed in the adult population, with glioblastoma contributing to 16.4% of all primary brain tumor cases. The rising burden of this brain tumor along with the growing aging population more susceptible to developing the condition is poised to augment the North America glioma market demand in the forecast period.
The market value is influenced by the presence of a supportive regulatory framework that expedites the introduction of new treatments and diagnostic techniques. For instance, in February 2024, Servier Pharmaceuticals LLC’s novel dual mIDH1/2 inhibitor vorasidenib (AG-881) new drug application was accepted and granted priority review by the United States Food and Drug Administration (FDA) for the treatment of patients with IDH-mutant diffuse glioma, a malignant and incurable brain tumor. The submission acceptance was prompted based on the positive findings of the phase 3 INDIGO trial. Moreover, to improve the diagnosis and management of glioma, the FDA granted fast-track designation to a PET imaging agent TLX101-CDx developed by Telix Pharmaceuticals Limited for use in progressive or recurrent glioma in April 2024 . Thus, the surge in approvals of advanced glioma therapies and diagnostic methods is anticipated to elevate the market value in the coming years.
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Diagnosis
Market Breakup by Treatment Type
Market Breakup by Route of Administration
Market Breakup by Country
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
This leading research-based global biopharmaceutical company invests a substantial portion of its total R&D budget in the area of oncology and is actively involved in the clinical development of glioma drugs.
This Swiss multinational pharmaceutical company has a prominent presence in the market. Its FDA-approved Tafinlar + Mekinist is indicated for pediatric patients with BRAF V600E low-grade glioma.
Johnson & Johnson, an American multinational, pharmaceutical, and medical technologies company, is engaged in merger and acquisition activities to expand its market presence. It is also involved in the research and development of innovative glioma treatments.
Merck & Co., Inc., a leading science and technology company, leverages strategic collaborations to accelerate the market entry of cancer drug candidates and develops prescription products related to the treatment of brain tumors.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market include Roche Holding AG, Bristol-Myers Squibb Company, Amgen Inc., AstraZeneca PLC, Eli Lilly and Company, and AbbVie Inc.
Upto 15% Off
USD
$2699 $2429
$4299 $3869
$5799 $4949
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The North America glioma market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 3.22% during the forecast period of 2026-2035 and is likely to reach a market value of USD 1.41 Billion by 2035.
The rising prevalence of glioma along with the growing aging population is fuelling the demand for the market.
One of the significant trends in the market is the increased approval of advanced glioma therapies. For instance, in February 2024, Servier Pharmaceuticals LLC’s vorasidenib (AG-881) new drug application was accepted and granted priority review by the FDA for the treatment of patients with IDH-mutant diffuse glioma.
Based on the type, the market is segmented into astrocytoma, oligodendroglioma, and glioblastoma.
By diagnosis, the market is divided into angiograms, magnetic resonance imaging (MRI), computerized tomography (CT), and surgical biopsy, among others.
The market breakup by treatment type includes chemotherapy, radiation, and surgery.
The market breakup by route of administration includes oral and parenteral.
The market segmentation by countries includes the United States and Canada.
The key players in the market are Pfizer Inc., Novartis AG, Johnson & Johnson, Merck & Co., Inc., Roche Holding AG, Bristol-Myers Squibb Company, Amgen Inc., AstraZeneca PLC, Eli Lilly and Company, and AbbVie Inc.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Diagnosis |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share